Finanzwire Finanzwire
Basculer en Français
10651 Companies
226541 Keywords
155026 Articles
119934 Press releases
Headlines Articles Press releases CAGE Bio Inc. Remove
  1. Home
  2. Companies
  3. CAGE Bio Inc.
Finanzwire
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 01/09/2025 at 21:05, 1 year 5 months ago

    CAGE Bio Launches Phase 2b Trial for Atopic Dermatitis Treatment CGB-500

    Phase 2B Trial Atopic Dermatitis CAGE Bio CGB-500 Ionic Liquid Technology
  • PRESS RELEASE

    published on 01/09/2025 at 21:00, 1 year 5 months ago

    CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis

    CAGE Bio initiates Phase 2b trial for CGB-500, a topical JAK inhibitor ointment for atopic dermatitis. High efficacy, low side-effects. Improving patient outcomes
    Phase 2B Trial Atopic Dermatitis CAGE Bio CGB-500 Topical Therapy
    Logo of CAGE Bio Inc.
  • PRESS RELEASE

    published on 08/03/2023 at 16:45, 2 years 10 months ago

    CAGE Bio Announces Positive Topline Results From its Double-Blind Phase 2 Study Evaluating an Ionic Liquid formulation of 1% Tofacitinib In Patients with Atopic Dermatitis

    Logo of CAGE Bio Inc.
Accesswire
  • Published on 06/27/2026 at 00:00, 30 minutes ago

    Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010

  • Published on 06/26/2026 at 23:00, 1 hour 30 minutes ago

    Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting

  • Published on 06/26/2026 at 22:50, 1 hour 40 minutes ago

    Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada

  • Published on 06/26/2026 at 22:15, 2 hours 15 minutes ago

    Revive Therapeutics Announces Proposed Private Placement

  • Published on 06/26/2026 at 15:05, 9 hours 25 minutes ago

    Vox Royalty Sells I-80 Gold Offtake Stream

View all ACCESSWIRE
EQS Group
  • Published on 06/27/2026 at 00:05, 25 minutes ago

    EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss

  • Published on 06/27/2026 at 00:04, 26 minutes ago

    Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering

  • Published on 06/26/2026 at 23:36, 54 minutes ago

    Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering

  • Published on 06/26/2026 at 23:36, 54 minutes ago

    EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share

  • Published on 06/26/2026 at 23:27, 1 hour 3 minutes ago

    EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE

View all EQS
Les Echos
  • Published on 06/26/2026 at 17:45, 6 hours 45 minutes ago

    Combined General Meeting, June 25, 2026

  • Published on 06/26/2026 at 14:44, 9 hours 46 minutes ago

    Safran information

  • Published on 06/26/2026 at 07:00, 17 hours 30 minutes ago

    Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel

  • Published on 06/25/2026 at 17:50, 1 day 6 hours ago

    DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS

  • Published on 06/25/2026 at 07:30, 1 day 17 hours ago

    Gimv signs an agreement to acquire Groupe Cap Vert, France’s leading multi-specialist provider of tree and vegetation critical management services, from Ambienta.

View all LES ECHOS COMFI WIRE

With finanzwire.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

Finanzwire

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

© 2026 Finanzwire

Contact Authors Cookies policy Terms and conditions Privacy policy